Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 222110
  • calendar_today Published On: Jun, 2021
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Filgrastim

Pefigrastim

Lipefigrastim

Market segment by Application, can be divided into

Oncology

Blood Disease

Other

Market segment by players, this report covers

Amgen

Kyowa Kirin

Chugai Pharmaceutical

Novartis

Teva

Pfizer

Merck

Dong-A Socio

Intas

GenSci

Dr. Reddy

Amoytop

North China Pharmaceutical

SL Pharm

Hayao Group

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs, with revenue, gross margin and global market share of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs from 2019 to 2021.

Chapter 3, the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market forecast, by regions, type and application, with revenue, from 2021 to 2026.

Chapter 11 and 12, to describe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs

1.2 Classification of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs by Type

1.2.1 Overview: Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type in 2020

1.2.3 Filgrastim

1.2.4 Pefigrastim

1.2.5 Lipefigrastim

1.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Application

1.3.1 Overview: Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Oncology

1.3.3 Blood Disease

1.3.4 Other

1.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size & Forecast

1.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast by Region

1.5.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region, (2016-2021)

1.5.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Prospect (2016-2026)

1.5.4 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Prospect (2016-2026)

1.5.6 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Drivers

1.6.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Restraints

1.6.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Trends Analysis

2 Company Profiles

2.1 Amgen

2.1.1 Amgen Details

2.1.2 Amgen Major Business

2.1.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.1.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Amgen Recent Developments and Future Plans

2.2 Kyowa Kirin

2.2.1 Kyowa Kirin Details

2.2.2 Kyowa Kirin Major Business

2.2.3 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.2.4 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Kyowa Kirin Recent Developments and Future Plans

2.3 Chugai Pharmaceutical

2.3.1 Chugai Pharmaceutical Details

2.3.2 Chugai Pharmaceutical Major Business

2.3.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.3.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Chugai Pharmaceutical Recent Developments and Future Plans

2.4 Novartis

2.4.1 Novartis Details

2.4.2 Novartis Major Business

2.4.3 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.4.4 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Novartis Recent Developments and Future Plans

2.5 Teva

2.5.1 Teva Details

2.5.2 Teva Major Business

2.5.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.5.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Teva Recent Developments and Future Plans

2.6 Pfizer

2.6.1 Pfizer Details

2.6.2 Pfizer Major Business

2.6.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.6.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Pfizer Recent Developments and Future Plans

2.7 Merck

2.7.1 Merck Details

2.7.2 Merck Major Business

2.7.3 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.7.4 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Merck Recent Developments and Future Plans

2.8 Dong-A Socio

2.8.1 Dong-A Socio Details

2.8.2 Dong-A Socio Major Business

2.8.3 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.8.4 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Dong-A Socio Recent Developments and Future Plans

2.9 Intas

2.9.1 Intas Details

2.9.2 Intas Major Business

2.9.3 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.9.4 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Intas Recent Developments and Future Plans

2.10 GenSci

2.10.1 GenSci Details

2.10.2 GenSci Major Business

2.10.3 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.10.4 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 GenSci Recent Developments and Future Plans

2.11 Dr. Reddy

2.11.1 Dr. Reddy Details

2.11.2 Dr. Reddy Major Business

2.11.3 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.11.4 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Dr. Reddy Recent Developments and Future Plans

2.12 Amoytop

2.12.1 Amoytop Details

2.12.2 Amoytop Major Business

2.12.3 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.12.4 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Amoytop Recent Developments and Future Plans

2.13 North China Pharmaceutical

2.13.1 North China Pharmaceutical Details

2.13.2 North China Pharmaceutical Major Business

2.13.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.13.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.13.5 North China Pharmaceutical Recent Developments and Future Plans

2.14 SL Pharm

2.14.1 SL Pharm Details

2.14.2 SL Pharm Major Business

2.14.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.14.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.14.5 SL Pharm Recent Developments and Future Plans

2.15 Hayao Group

2.15.1 Hayao Group Details

2.15.2 Hayao Group Major Business

2.15.3 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

2.15.4 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.15.5 Hayao Group Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Market Share

3.2.2 Top 10 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Market Share

3.2.3 Market Competition Trend

3.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Market Share by Type (2016-2021)

4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2016-2021)

5.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2026)

6.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2026)

6.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country

6.3.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2016-2026)

6.3.2 United States Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

6.3.3 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

6.3.4 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2026)

7.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2026)

7.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country

7.3.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2016-2026)

7.3.2 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

7.3.3 France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

7.3.5 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

7.3.6 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2026)

8.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2026)

8.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region

8.3.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Region (2016-2026)

8.3.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

8.3.3 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

8.3.4 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

8.3.5 India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

8.3.7 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2026)

9.2 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2026)

9.3 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country

9.3.1 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2016-2026)

9.3.2 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

9.3.3 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2026)

10.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2026)

10.3 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country

10.3.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2016-2026)

10.3.2 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

10.3.4 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million) by Region (2016-2021)

Table 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Region (2021-2026)

Table 6. Amgen Corporate Information, Head Office, and Major Competitors

Table 7. Amgen Major Business

Table 8. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 9. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Kyowa Kirin Corporate Information, Head Office, and Major Competitors

Table 11. Kyowa Kirin Major Business

Table 12. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 13. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Chugai Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 15. Chugai Pharmaceutical Major Business

Table 16. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 17. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Novartis Corporate Information, Head Office, and Major Competitors

Table 19. Novartis Major Business

Table 20. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 21. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Teva Corporate Information, Head Office, and Major Competitors

Table 23. Teva Major Business

Table 24. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 25. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Pfizer Corporate Information, Head Office, and Major Competitors

Table 27. Pfizer Major Business

Table 28. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 29. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Merck Corporate Information, Head Office, and Major Competitors

Table 31. Merck Major Business

Table 32. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 33. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Dong-A Socio Corporate Information, Head Office, and Major Competitors

Table 35. Dong-A Socio Major Business

Table 36. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 37. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Intas Corporate Information, Head Office, and Major Competitors

Table 39. Intas Major Business

Table 40. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 41. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. GenSci Corporate Information, Head Office, and Major Competitors

Table 43. GenSci Major Business

Table 44. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 45. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Dr. Reddy Corporate Information, Head Office, and Major Competitors

Table 47. Dr. Reddy Major Business

Table 48. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 49. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Amoytop Corporate Information, Head Office, and Major Competitors

Table 51. Amoytop Major Business

Table 52. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 53. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. North China Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 55. North China Pharmaceutical Major Business

Table 56. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 57. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 58. SL Pharm Corporate Information, Head Office, and Major Competitors

Table 59. SL Pharm Major Business

Table 60. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 61. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 62. Hayao Group Corporate Information, Head Office, and Major Competitors

Table 63. Hayao Group Major Business

Table 64. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product and Solutions

Table 65. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 66. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million) by Players (2019-2021)

Table 67. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Players (2019-2021)

Table 68. Breakdown of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)

Table 69. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Head Office, Products and Services Provided

Table 70. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Mergers & Acquisitions in the Past Five Years

Table 71. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs New Entrants and Expansion Plans

Table 72. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million) by Type (2016-2021)

Table 73. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type (2016-2021)

Table 74. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Forecast by Type (2021-2026)

Table 75. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2021)

Table 76. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Forecast by Application (2021-2026)

Table 77. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2021) & (USD Million)

Table 78. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (USD Million)

Table 79. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2021) & (USD Million)

Table 80. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (USD Million)

Table 81. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2016-2021) & (USD Million)

Table 82. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026) & (USD Million)

Table 83. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2021) & (USD Million)

Table 84. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (USD Million)

Table 85. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2021) & (USD Million)

Table 86. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (USD Million)

Table 87. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2016-2021) & (USD Million)

Table 88. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026) & (USD Million)

Table 89. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2021) & (USD Million)

Table 90. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (USD Million)

Table 91. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2021) & (USD Million)

Table 92. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (USD Million)

Table 93. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Region (2016-2021) & (USD Million)

Table 94. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Region (2021-2026) & (USD Million)

Table 95. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2021) & (USD Million)

Table 96. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (USD Million)

Table 97. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2021) & (USD Million)

Table 98. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (USD Million)

Table 99. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2016-2021) & (USD Million)

Table 100. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026) & (USD Million)

Table 101. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2016-2021) & (USD Million)

Table 102. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Type (2021-2026) & (USD Million)

Table 103. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2016-2021) & (USD Million)

Table 104. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Application (2021-2026) & (USD Million)

Table 105. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2016-2021) & (USD Million)

Table 106. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Picture

Figure 2. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type in 2020

Figure 3. Filgrastim

Figure 4. Pefigrastim

Figure 5. Lipefigrastim

Figure 6. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application in 2020

Figure 7. Oncology Picture

Figure 8. Blood Disease Picture

Figure 9. Other Picture

Figure 10. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 11. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Forecast (2016-2026) & (USD Million)

Figure 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Region (2016-2026)

Figure 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Region in 2020

Figure 14. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 15. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Drivers

Figure 20. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Restraints

Figure 21. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Trends

Figure 22. Amgen Recent Developments and Future Plans

Figure 23. Kyowa Kirin Recent Developments and Future Plans

Figure 24. Chugai Pharmaceutical Recent Developments and Future Plans

Figure 25. Novartis Recent Developments and Future Plans

Figure 26. Teva Recent Developments and Future Plans

Figure 27. Pfizer Recent Developments and Future Plans

Figure 28. Merck Recent Developments and Future Plans

Figure 29. Dong-A Socio Recent Developments and Future Plans

Figure 30. Intas Recent Developments and Future Plans

Figure 31. GenSci Recent Developments and Future Plans

Figure 32. Dr. Reddy Recent Developments and Future Plans

Figure 33. Amoytop Recent Developments and Future Plans

Figure 34. North China Pharmaceutical Recent Developments and Future Plans

Figure 35. SL Pharm Recent Developments and Future Plans

Figure 36. Hayao Group Recent Developments and Future Plans

Figure 37. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Players in 2020

Figure 38. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 39. Global Top 3 Players Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share in 2020

Figure 40. Global Top 10 Players Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share in 2020

Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 42. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Type in 2020

Figure 43. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share Forecast by Type (2021-2026)

Figure 44. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Application in 2020

Figure 45. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share Forecast by Application (2021-2026)

Figure 46. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Type (2016-2026)

Figure 47. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Application (2016-2026)

Figure 48. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Country (2016-2026)

Figure 49. United States Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 50. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 51. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 52. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Type (2016-2026)

Figure 53. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Application (2016-2026)

Figure 54. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Country (2016-2026)

Figure 55. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. United Kingdom Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 58. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Type (2016-2026)

Figure 61. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Application (2016-2026)

Figure 62. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Region (2016-2026)

Figure 63. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 67. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Type (2016-2026)

Figure 70. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Application (2016-2026)

Figure 71. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Country (2016-2026)

Figure 72. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Type (2016-2026)

Figure 75. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Market Share by Application (2016-2026)

Figure 76. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Country (2016-2026)

Figure 77. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 78. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 79. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 80. Methodology

Figure 81. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz